It mediates its action through insulin-dependent and AMP-activated protein kinase (AMPK)-dependent effects, by selectively targeting CSCs, reversing multidrug resistance and inhibiting tumour metastasis and acts on mammalian target of rapamycin (mTOR) pathway inhibition [97,98,99]. This evidence concerns the gene MTOR and neoplasm.